Nursing Pharmacology:  Antiviral Drugs

• Antiretroviral Drugs Used in Treating HIV Infection

  • →Non-nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NNRTI): (continued)

    • Efavirenz (Sustiva)

    • Efavirenz (Sustiva) has been described as potent antiretroviral drug, highly active with respect to HIV-1 inhibtion.¹ 

      • Efavirenz is ineffective inhibiting HIV-2 or other retroviruses.¹ 

    • Mutations and Resistance to Efavirenz (Sustiva)

      • Efavirenz resistance commonly follows a mutation at codon 103 of HIV-1 reverse transcriptase.¹ 

        • This mutation involves a change from the wild type lysine amino acid to an asparagine (K103N) or serine (K103S) amino acid.⁸ 

          • In addition to the K103N mutation, the Y181C mutation is also sufficient to result in virologic treatment failure.¹

    • Pharmacokinetics

      • Efavirenz (Sustiva) is well absorbed from the G.I. tract with peak plasma levels noted about five hours after administration.¹  

        • The oral bioavailability is about 45%. A high-fat meal increases bioavailability, as measured by area under the curve (AUC),  by about 22 %.⁷  

          • Accordingly, this drug is preferably administered on an empty stomach.

        • The half-life for efavirenz is unusually long, approximately 2 days.⁷  

          • Efavirenz is extensively bound to plasma albumin (~99%) and CSF (cerebrospinal fluid) levels correspond to about 0.75% of the plasma drug concentration.^1,7   

          • Despite relatively low CSF drug penetration, many highly significant adverse reactions to efavirenz administration are central nervous system in nature.¹

      • Efavirenz is metabolized using the hepatic cytochrome P450 oxidative metabolizing system.⁶  

        • Efavirenz is a substrate mainly for the cytochrome P450 enzyme isoforms CYP2B6 and CYP3A4 isoforms.

          • Efavirenz is not subject to renal excretion to any appreciable extent and as a result no dose adjustment is typically required in renal failure.^6,1  

        • Since the antiretroviral protease inhibitors are also substrates for CYP3A4, dosage adjustments are likely required.

          • Efavirenz reduces plasma concentrations of several central nervous system drugs including phenytoin, phenobarbital and carbamazepine.¹ 

          • Efavirenz decreases rifabutin area-under-the- curve (AUC) by about 40%.

          • With respect to HIV antiretroviral protease inhibitors, some drugs reduce plasma concentrations while others elevate plasma levels.¹

            • Agents exhibiting decreased  plasma levels following efavirenz administration include saquinavir, indinavir and amprinavir.

            • By contrast, protease inhibitors associated with higher plasma concentrations following efavirenz include ritonavir and nelfinavir.¹  

          • Agents that, as a result of induction of cytochrome P450 isoforms associated with efavirenz metabolism (CYP2B6 and CYP3A4), such as carbamazepine, phenytoin or phenobarbital, should not be used as efavirenz clearance would likely be increased.

          • Similar to nevirapine, efavirenz reduces methadone plasma levels and can induce acute opioid withdrawal.⁶

          • Efavirenz doses may require adjustment when the drug is co-administered with voriconazole but apparently no adjustment is required when coadministered with fluconazole.⁶

    • Adverse Effects

      •  The two major classes of efavirenz (Sustiva) toxicities relate to the central nervous system (CNS) and reproduction (teratogenicity).⁶  

        • One view concerning efavirenz use in pregnancy is that, since efavirenz is the the only antiretroviral agent clearly teratogenic in primates, the drug should not be administered during pregnancy or to women attempting conception or in sexually active women not using contraception.

        • Efavirenz administration may cause neural tube defects in the newborn.⁶  

        • Because neural tube defects occurs only during the first 5-6 weeks of pregnancy, an alternate view is that efavirenz-based protocols may be initiated in pregnant women after the initial eight week gestation period.¹⁶ 

      • Perhaps the more prominent efavirenz adverse effect involves the central nervous system since about 50% of patients exhibit some CNS/psychiatric side effects.

        • However, <5% of patients discontinued efavirenz because of CNS adverse effects.

        • The range of adverse effects reported includes dizziness, diminished concentration, dream abnormalities, dysphoria and insomnia.

        • Efavirenz, when first administered, may predispose to depression, hallucinations and/or mania; however, these effects tend to abate within the first month of therapy.

      • Miscellaneous side effects include:⁷

        • Nausea and vomiting

        • Crystalluria

        • Increases in liver enzyme values

        • Increases in total serum cholesterol on the order of 10%-20%.

        • Skin rash may occur early in efavirenz treatment with a frequency of about 30% of patients.⁷  

          • This rash tends to be mild to moderate and usually resolves without the need to discontinue efavirenz treatment.⁷

          • "Maculo-papular drug rash due to efavirenz"¹⁷ 

    • Therapeutics

      • Efavirenz (Sustiva) has been until recently classified as a preferred agent useful in beginning antiretroviral protocol treatment.⁶  

        • This agent, when combined with other drugs, provides long-lasting suppression of HIV-1 viral replication.

        • However, efavirenz administration may result in central nervous system adverse effects.

          • Up to 50% of patients receiving efavirenz may experience CNS adverse effects, particularly during the initial weeks of treatment.⁶  

            • Such adverse effects include:

              • Insomnia,

              • Dizziness and

              • Poor concentration.

            • Less frequently, the following more serious side effects have been reported:

              • Hallucinations

              • Depression

              • Psychosis and

              • Suicidality

            • For these reasons efavirenz may be inappropriate for use in patients diagnosed with pre-existing psychiatric conditions.⁶  

        • Recently (2015) efavirenz has been moved from the "Recommended" to the "Alternative" category due to adverse effects found both in clinical trial and clinical practice.⁹  

          • Most of the concern is due to CNS-related toxicities as described above and the possible relationship between suicidality and efavirenz administration.

          • This change in status applies to initial combination protocols for the antiretroviral drug naïve patient and is a revision to the May 1, 2014 HIV-1 Treatment Guideline, noted in the April 8, 2015 publication.⁹

        • Efavirenz (Sustiva) was the first antiretroviral drug FDA-approved for once-daily dosing.¹  

          • The rapid development of resistance to the antiretroviral effects of efavirenz in monotherapy has led to its use as part of multidrug protocols.

          • Efavirenz has been widely used (developed world) due to convenience, effectiveness and tolerability, although this agent is now classifed in the Alternative" regimen category as noted earlier.¹

            • One popular combined agent involves efavirenz coformulated with tenofovir and emtricitabine (Atripla).

              •  

                Atripla (Efavirenz, Emtricitabine, and Tenofovir)

                The long half-life of efavirenz is very important in this combination treatment should suboptimal adherence to medication is noted in a patient.18   Should doses be missed, the long-half life of efavirenz assures its presence; however, the other agents in this combination are no longer active due to their shorter half-lives.  As a result, during periods of missed doses, the patient is on essentially efavirenz monotherapy and susceptible to inactivating mutations.18

              • Efavirenz-containing multidrug protocols may provide the best long-term clinical responses.

            • Until recently, efavirenz along with two nucleoside reverse transcriptase inhibitors was categorized as a “Preferred” regimen in the treatment-naïve individual.⁹  

              • Efavirenz in the generic version has been used increasingly as part of treatment regimens in "resource-poor" countries due to relatively better toxicity profiles when compared to nevirapine.

                • Also, efavirenz may be combined with rifampin for management of tuberculosis.¹

References

Flexner C Antiretroviral Agents and Treatment of HIV Infection, Chapter 59  in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edition (Brunton LL Chabner BA Knollmann BC, eds; Brunton LL, ed; Blumenthal DK  Murri N Hilal-Dandan R, assoc eds, Knollmann BC, consulting ed, on-line edition) The McGraw-Hill Companies, 2011. Fauci AS Lane HC Chapter 226, Human Immunodeficiency Virus Disease:  AIDS and Related Disorders, in Harrison's Online   (Kasper DL Fauci AS Hauser SL Longo DL Jameson JL Loscalzo J, Eds.),  Harrison's Principles of Internal Medicine, 19th edition, The McGraw-Hill Companies, Inc. 2015 (on-line edition) Longo DL Fauci AS  188, The Human Retroviruses, in Harrison's Online   (Dan L. Longo, Anthony S. Fauci, Dennis L. Kasper, Stephen L. Hauser, J. Larry Jameson, Joseph Loscalzo, Eds.),  Harrison's Principles of Internal Medicine, 18th edition, The McGraw-Hill Companies, Inc. 2012. Woster PM Chapter 43:  Antiviral Agents and Protease Inhibitors in Foye's Principles of Medicinal Chemistry 6e, Lemke, TL Williams DA, eds; Roche VG Zito SW, asst eds) Wolters Kluwer|Lippincott Williams & Wilkins 1214, 2008. HIV Overview:  The HIV Life Cycle, Education Materials, AIDSinfo, NIH http://aidsinfo.nih.gov/education-materials/fact-sheets/19/73/the-hiv-life-cycle Tsibris AMN Hirsch MS Chapter 130 Antiretroviral Therapy for Human Immunodeficiency Virus Infection in Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8e (Bennett JE Bolin R Blaser, eds) Elsevier, Inc/Saunders 2015, online version. Safrin S Chapter 49:  Antiviral Agents:  Antiretroviral Agents in Basic & Clinical Pharmacology 13e (Katzung BG Trevor AJ, eds) 2015, online edition. Wensing AM Calvez V Gunthard JF Johnson VA Paredes R Pillay D Shafer RW Richman DD Special Contribution:  2014 Update of the Drug Resistance Multations in HIV-1 Topics in Antivral Medicine 22(3)  June/July 2014, https://www.iasusa.org/sites/default/files/tam/22-3-642.pdf AIDSinfo:  Guidelines for the Use of Antriretroviral Agents in HIV-1-Infected Adults and Adolescents https://aidsinfo.nih.gov/guidelines (2015) NNRTI Resistance Notes (Stanford University, HIV Drug Resistance Database), March 2, 2014 http://hivdb.stanford.edu/DR/NNRTIResiNote.html Mackie N Chapter 2  Resistance to non-nucleoside reverse transcriptase inhibitors in Antiretroviral Resistance in Clinical Practice, Geretti AM, ED) London, 2006 http://www.ncbi.nlm.nih.gov/books/NBK2249/ Gatanaga H Hachiya A Kimura S Oka S Mutations other than 103N in human immunnodeficiency virus type 1 reverse transcriptase (R) emerge from K103R polymorphism under non-nucleoside RT inhibitor pressure.  Virology 344(2) 354-362 20 January 2006. http://www.sciencedirect.com/science/article/pii/S0042682205005660 DNA Codon Table https://en.wikipedia.org/wiki/DNA_codon_table Haas DW Ribaudo HJ Kim RB Tierney C Wilkinson GR Gulick RM Clifford DB Hulgan T Marzolini C Acosta EP Pharmacogenetics of efavirenz and central nervous sustem side effects:  an Adult AIDS Clinical Trials Group study. AIDS 18(18):  2391-2400, December 3, 2004 http://www.ncbi.nlm.nih.gov/pubmed/15622315 Weiss M Weiner J Carey M Shaliba E Efavirenz:  A non-nucleoside reverse transcriptase inhibitor https://www.youtube.com/watch?v=GKuXxn1gqkY AIDSinfo Recommendations for Use of Antiretroviral Drugs in Pregnana HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States (Updated March 28, 2014) https://aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_449.pdf Dermatology and Anti-retroviral Therapy:  Efavirenz http://hivpv.org/Home/SideEffects/Dermatology.aspx Wood BR NNRTI Resistance https://www.youtube.com/watch?v=mcHWUMvYubs

 

Disclaimer

This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information  thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.